Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities

BMC Research Notes

Hans Biesalski⁷  Harrie Weinans⁹  Christiane Schön⁵  Karel Pavelka¹  Ali Mobasheri³  Timothy McAlindon⁸  Gabriel Herrero-Beaumont⁶  Xavier Chevalier²  Yves Henrotin⁴ 

[1] Institute of Rheumatology, Prague, Czech Republic;Rheumatology Department, Mondor Hospital, Créteil, France;Musculoskeletal Research Group, Division of Veterinary Medicine, School of Veterinary Medicine and Science, Faculty of Medicine and Health Sciences, The University of Nottingham, Sutton Bonington Campus, Sutton Bonington, Leicestershire, LE12 5RD, United Kingdom;Princess Paola Hospital, Marche-en-Famenne, Belgium;UMC Utrecht, Department of Orthopedics, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands;Bone and Joint Research Unit, Service of Rheumatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain;Department of Biological Chemistry and Nutrition, Garbenstrasse 30, Stuttgart, D 70593, Germany;Division of Rheumatology, Tufts Medical Center, 800 Washington Street, Box 406, Boston, MA, 02111, USA;Erasmus University Medical Center, Rotterdam, The Netherlands

关键词: Prevention;    Treatment;    Osteoarthritis;    Glucosamine;   

Others  :  1143148
DOI  :  10.1186/1756-0500-6-115

 received in 2012-10-15, accepted in 2013-03-07,  发布年份 2013

【 摘 要 】

The aim of this paper was to provide an overview of the current knowledge and understanding of the potential beneficial physiological effects of glucosamine (GlcN) on joint health. The objective was to reach a consensus on four critical questions and to provide recommendations for future research priorities. To this end, nine scientists from Europe and the United States were selected according to their expertise in this particular field and were invited to participate in the Hohenheim conference held in August 2011. Each expert was asked to address a question that had previously been posed by the chairman of the conference. Based on a systematic review of the literature and the collection of recent data, the experts documented the effects of GlcN on cartilage ageing, metabolic/kinetic and maintenance of joint health as well as reduction of risk of OA development. After extensive debate and discussion the expert panel addressed each question and a general consensus statement was developed, agreeing on the current state-of-the-art and future areas for basic and clinical studies. This paper summarizes the available evidence for beneficial effects of GlcN on joint health and proposes new insight into the design of future clinical trials aimed at identifying beneficial physiological effect of GlcN on joint tissues.

【 授权许可】

   
2013 Henrotin et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
• [2]Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123.
• [3]Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808.
• [4]Henrotin Y, Mobasheri A, Marty M: Is There Any Scientific Evidence For the Use of Glucosamine in the Management of Human Osteoarthritis. Arthritis Res Ther 2012. In press
• [5]Altman RD, Abramson S, Bruyere O, Clegg D, Herrero-Beaumont G, Maheu E, Moskowitz R, Pavelka K, Reginster JY: Commentary: osteoarthritis of the knee and glucosamine. Osteoarthr Cartil 2006, 14:963-966.
• [6]Hamerman D: Biology of the aging joint. Clin Geriatr Med 1998, 14:417-433.
• [7]Lotz MK, Carames B: Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA. Nat Rev Rheumatol 2011, 7:579-587.
• [8]Buckwalter JA, Mankin HJ: Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course Lect 1998, 47:487-504.
• [9]Shane Anderson A, Loeser RF: Why is osteoarthritis an age-related disease? Best Pract Res Clin Rheumatol 2010, 24:15-26.
• [10]Loeser RF: Aging and osteoarthritis. Curr Opin Rheumatol 2011, 23:492-496.
• [11]Calamia V, Ruiz-Romero C, Rocha B, Fernandez-Puente P, Mateos J, Montell E, Verges J, Blanco FJ: Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther 2010, 12:R138. BioMed Central Full Text
• [12]Graeser AC, Giller K, Wiegand H, Barella L, Rimbach G, Boesch Saadatmandi C: Synergistic chondroprotective effect of alpha-tocopherol, ascorbic acid, and selenium as well as glucosamine and chondroitin on oxidant induced cell death and inhibition of matrix metalloproteinase-3--studies in cultured chondrocyte. Molecules 2010, 15:27-39.
• [13]Valvason C, Musacchio E, Pozzuoli A, Ramonda R, Aldegheri R, Punzi L: Influence of glucosamine sulphate on oxidative stress in human osteoarthritic chondrocytes: effects on HO-1, p22(Phox) and iNOS expression. Rheumatology (Oxford) 2008, 47:31-35.
• [14]Tardio L, Herrero-Beaumont G, Gómez-Barrena E, Andrés-Bergós J, Largo R: Osteoarthritis leads to increased levels of protein O-linked N-acetylglucosamine in the cartilage. Osteoarthr Cartil 2010, 18:S111.
• [15]Torres CR, Hart GW: Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem 1984, 259:3308-3317.
• [16]Hart GW, Housley MP, Slawson C: Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 2007, 446:1017-1022.
• [17]Hanover JA, Krause MW, Love DC: The hexosamine signaling pathway: O-GlcNAc cycling in feast or famine. Biochim Biophys Acta 2010, 1800:80-95.
• [18]Zachara NE, Hart GW: Cell signaling, the essential role of O-GlcNAc. Biochim Biophys Acta 2006, 1761:599-617.
• [19]Chatham JC, Not LG, Fulop N, Marchase RB: Hexosamine biosynthesis and protein O-glycosylation: the first line of defense against stress, ischemia, and trauma. Shock 2008, 29:431-440.
• [20]Jawed H, Anjum S, Awan SI, Simjee SU: Anti-arthritic effect of GN1, a novel synthetic analog of glucosamine, in the collagen-induced arthritis model in rats. Inflamm Res 2011, 60:1113-1120.
• [21]Hua J, Suguro S, Hirano S, Sakamoto K, Nagaoka I: Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflamm Res 2005, 54:127-132.
• [22]Dodge GR, Jimenez SA: Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthr Cartil 2003, 11:424-432.
• [23]Byron CR, Stewart MC, Stewart AA, Pondenis HC: Effects of clinically relevant concentrations of glucosamine on equine chondrocytes and synoviocytes in vitro. Am J Vet Res 2008, 69:1129-1134.
• [24]Mobasheri A, Bondy CA, Moley K, Mendes AF, Rosa SC, Richardson SM, Hoyland JA, Barrett-Jolley R, Shakibaei M: Facilitative glucose transporters in articular chondrocytes. Expression, distribution and functional regulation of GLUT isoforms by hypoxia, hypoxia mimetics, growth factors and pro-inflammatory cytokines. Adv Anat Embryol Cell Biol 2008, 200(1):1-84. p following vi
• [25]Mobasheri A, Richardson S, Mobasheri R, Shakibaei M, Hoyland JA: Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. Histol Histopathol 2005, 20:1327-1338.
• [26]Mobasheri A: Role of chondrocyte death and hypocellularity in ageing human articular cartilage and the pathogenesis of osteoarthritis. Med Hypotheses 2002, 58:193-197.
• [27]Rosa SC, Goncalves J, Judas F, Mobasheri A, Lopes C, Mendes AF: Impaired glucose transporter-1 degradation and increased glucose transport and oxidative stress in response to high glucose in chondrocytes from osteoarthritic versus normal human cartilage. Arthritis Res Ther 2009, 11:R80. BioMed Central Full Text
• [28]Uitterlinden EJ, Jahr H, Koevoet JL, Bierma-Zeinstra SM, Verhaar JA, Weinans H, van Osch GJ: Glucosamine reduces anabolic as well as catabolic processes in bovine chondrocytes cultured in alginate. Osteoarthr Cartil 2007, 15:1267-1274.
• [29]Virkamaki A, Yki-Jarvinen H: Allosteric regulation of glycogen synthase and hexokinase by glucosamine-6-phosphate during glucosamine-induced insulin resistance in skeletal muscle and heart. Diabetes 1999, 48:1101-1107.
• [30]Tesoriere G, Vento R, Calvaruso G: Inhibitory effect of D-glucosamine on glycolysis in bovine retina. Biochim Biophys Acta 1975, 385:58-67.
• [31]Hinderlich S, Berger M, Schwarzkopf M, Effertz K, Reutter W: Molecular cloning and characterization of murine and human N-acetylglucosamine kinase. Eur J Biochem 2000, 267:3301-3308.
• [32]Block JA, Oegema TR, Sandy JD, Plaas A: The effects of oral glucosamine on joint health: is a change in research approach needed? Osteoarthr Cartil 2010, 18:5-11.
• [33]Hubert C, Houari S, Lecomte F, Houbart V, De Bleye C, Fillet M, Piel G, Rozet E, Hubert P: Development and validation of a sensitive solid phase extraction/hydrophilic interaction liquid chromatography/mass spectrometry method for the accurate determination of glucosamine in dog plasma. J Chromatogr A 2010, 1217:3275-3281.
• [34]Roda A, Sabatini L, Barbieri A, Guardigli M, Locatelli M, Violante FS, Rovati LC, Persiani S: Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 844:119-126.
• [35]Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A: Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthr Cartil 2005, 13:1041-1049.
• [36]Biggee BA, Blinn CM, Nuite M, McAlindon TE, Silbert JE: Changes in serum levels of glucosamine and sulphate after ingestion of glucosamine sulphate with and without simultaneous ingestion of glucose. Ann Rheum Dis 2007, 66:1403-1404.
• [37]Zhong S, Zhong D, Chen X: Improved and simplified liquid chromatography/electrospray ionization mass spectrometry method for the analysis of underivatized glucosamine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 854:291-298.
• [38]Laverty S, Sandy JD, Celeste C, Vachon P, Marier JF, Plaas AH: Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum 2005, 52:181-191.
• [39]Persiani S, Rotini R, Trisolino G, Rovati LC, Locatelli M, Paganini D, Antonioli D, Roda A: Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthr Cartil 2007, 15:764-772.
• [40]Pastorini E, Rotini R, Guardigli M, Vecchiotti S, Persiani S, Trisolino G, Antonioli D, Rovati LC, Roda A: Development and validation of a HPLC-ES-MS/MS method for the determination of glucosamine in human synovial fluid. J Pharm Biomed Anal 2009, 50:1009-1014.
• [41]Jackson CG, Plaas AH, Sandy JD, Hua C, Kim-Rolands S, Barnhill JG, Harris CL, Clegg DO: The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthr Cartil 2010, 18:297-302.
• [42]Largo R, Martinez-Calatrava MJ, Sanchez-Pernaute O, Marcos ME, Moreno-Rubio J, Aparicio C, Egido J, Herrero-Beaumont G: Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. Am J Physiol Heart Circ Physiol 2009, 297:H268-276.
• [43]Miller KL, Clegg DO: Glucosamine and chondroitin sulfate. Rheum Dis Clin North Am 2011, 37:103-118.
• [44]Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J, Herrero-Beaumont G: Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr Cartil 2003, 11:290-298.
• [45]Bruyere O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gatterova J, Giacovelli G, Reginster JY: Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 2004, 11:138-143.
• [46]Bruyere O, Honore A, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, Seidel L, Reginster JY: Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthr Cartil 2003, 11:1-5.
• [47]Bruyere O, Pavelka K, Rovati LC, Gatterova J, Giacovelli G, Olejarova M, Deroisy R, Reginster JY: Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthr Cartil 2008, 16:254-260.
• [48]Wandel S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton NJ, Reichenbach S, Trelle S: Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010, 341:c4675.
• [49]EFSA Panel on Dietetic Products NaA: Scientific Opinion on the substantiation of a health claim related to glucosamine and maintenance of joints pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2011, 9:2476.
• [50]Ostojic SM, Arsic M, Prodanovic S, Vukovic J, Zlatanovic M: Glucosamine administration in athletes: effects on recovery of acute knee injury. Res Sports Med 2007, 15:113-124.
• [51]Yoshimura M, Sakamoto K, Tsuruta A, Yamamoto T, Ishida K, Yamaguchi H, Nagaoka I: Evaluation of the effect of glucosamine administration on biomarkers for cartilage and bone metabolism in soccer players. Int J Mol Med 2009, 24:487-494.
• [52]Chen HC, Shah S, Stabler TV, Li YJ, Kraus VB: Biomarkers associated with clinical phenotypes of hand osteoarthritis in a large multigenerational family: the CARRIAGE family study. Osteoarthr Cartil 2008, 16:1054-1059.
• [53]Sowers M, Zobel D, Weissfeld L, Hawthorne VM, Carman W: Progression of osteoarthritis of the hand and metacarpal bone loss. A twenty-year followup of incident cases. Arthritis Rheum 1991, 34:36-42.
• [54]Goldring MB, Otero M: Inflammation in osteoarthritis. Curr Opin Rheumatol 2011, 23:471-478.
• [55]Moreau M, Lussier B, Doucet M, Vincent G, Martel-Pelletier J, Pelletier JP: Efficacy of Licofelone in dogs with clinical osteoarthritis. Vet Rec 2007, 160(17):584-588.
• [56]Pelletier JP, Martel-Pelletier J: In vivo protective effects of prophylactic treatment with tiaprofenic acid or intraarticular corticosteroids on osteoarthritic lesions in the experimental dog model. J Rheumatol Suppl 1991, 27:127-130.
• [57]Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Abram F, Choquette D, Haraoui B, Beary JF, Cline GA, Meyer JM, Pelletier JP: Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis 2008, 67:683-688.
• [58]Imagawa K, de Andres MC, Hashimoto K, Pitt D, Itoi E, Goldring MB, Roach HI, Oreffo RO: The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes–implications for osteoarthritis. Biochem Biophys Res Commun 2011, 405:362-367.
• [59]Chiusaroli R, Piepoli T, Zanelli T, Ballanti P, Lanza M, Rovati LC, Caselli G: Experimental pharmacology of glucosamine sulfate. Int J Rheumatol 2011, 2011:939265.
• [60]Baron AD, Zhu JS, Zhu JH, Weldon H, Maianu L, Garvey WT: Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. J Clin Invest 1995, 96:2792-2801.
• [61]Simon RR, Marks V, Leeds AR, Anderson JW: A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev 2011, 27:14-27.
• [62]Puenpatom RA, Victor TW: Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med 2009, 121:9-20.
• [63]Giaccari A, Morviducci L, Zorretta D, Sbraccia P, Leonetti F, Caiola S, Buongiorno A, Bonadonna RC, Tamburrano G: In vivo effects of glucosamine on insulin secretion and insulin sensitivity in the rat: possible relevance to the maladaptive responses to chronic hyperglycaemia. Diabetologia 1995, 38:518-524.
• [64]Scroggie DA, Albright A, Harris MD: The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med 2003, 163:1587-1590.
• [65]Muniyappa R, Karne RJ, Hall G, Crandon SK, Bronstein JA, Ver MR, Hortin GL, Quon MJ: Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes 2006, 55:3142-3150.
• [66]Pham T, Cornea A, Blick KE, Jenkins A, Scofield RH: Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am J Med Sci 2007, 333:333-339.
• [67]Biggee BA, Blinn CM, Nuite M, Silbert JE, McAlindon TE: Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann Rheum Dis 2007, 66:260-262.
• [68]Dostrovsky NR, Towheed TE, Hudson RW, Anastassiades TP: The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. Osteoarthr Cartil 2011, 19:375-380.
• [69]Monauni T, Zenti MG, Cretti A, Daniels MC, Targher G, Caruso B, Caputo M, McClain D, Del Prato S, Giaccari A, Muggeo M, Bonora E, Bonadonna RC: Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes 2000, 49:926-935.
• [70]Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits P, Tack CJ: Short-term glucosamine infusion does not affect insulin sensitivity in humans. J Clin Endocrinol Metab 2001, 86:2099-2103.
• [71]Tannis AJ, Barban J, Conquer JA: Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthr Cartil 2004, 12:506-511.
• [72]Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G: Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001, (1):CD002946. Review. Update in: Cochrane Database Syst Rev. 2005;(2):CD002946. PMID:11279782
• [73]Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G: Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005, (2):CD002946. Review. PMID: 15846645
• [74]Marshall S, Yamasaki K, Okuyama R: Glucosamine induces rapid desensitization of glucose transport in isolated adipocytes by increasing GlcN-6-P levels. Biochem Biophys Res Commun 2005, 329:1155-1161.
• [75]Gouze JN, Bianchi A, Becuwe P, Dauca M, Netter P, Magdalou J, Terlain B, Bordji K: Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway. FEBS Lett 2002, 510:166-170.
• [76]Sandy JD, Gamett D, Thompson V, Verscharen C: Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998, 335(Pt 1):59-66.
• [77]Piperno M, Reboul P, Hellio Le Graverand MP, Peschard MJ, Annefeld M, Richard M, Vignon E: Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthr Cartil 2000, 8:207-212.
• [78]Gouze JN, Gouze E, Popp MP, Bush ML, Dacanay EA, Kay JD, Levings PP, Patel KR, Saran JP, Watson RS, Ghivizzani SC: Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res Ther 2006, 8:R173. BioMed Central Full Text
• [79]Petersen SG, Beyer N, Hansen M, Holm L, Aagaard P, Mackey AL, Kjaer M: Nonsteroidal anti-inflammatory drug or glucosamine reduced pain and improved muscle strength with resistance training in a randomized controlled trial of knee osteoarthritis patients. Arch Phys Med Rehabil 2011, 92:1185-1193.
• [80]Mobasheri A, Henrotin Y: Biomarkers of osteoarthritis: a review of recent research progress on soluble biochemical markers, published patents and areas for future development. Recent Patents on Biomarkers 2011, 1:25-43.
• [81]Henrotin Y, Deberg M, Mathy-Hartert M, Deby-Dupont G: Biochemical biomarkers of oxidative collagen damage. Adv Clin Chem 2009, 49:31-55.
• [82]Anandacoomarasamy A, Leibman S, Smith G, Caterson I, Giuffre B, Fransen M, Sambrook PN, March L: Weight loss in obese people has structure-modifying effects on medial but not on lateral knee articular cartilage. Ann Rheum Dis 2012, 71:26-32.
• [83]Kraus VB, McDaniel G, Worrell TW, Feng S, Vail TP, Varju G, Coleman RE: Association of bone scintigraphic abnormalities with knee malalignment and pain. Ann Rheum Dis 2009, 68:1673-1679.
• [84]Aghazadeh-Habashi A, Jamali F: The glucosamine controversy; a pharmacokinetic issue. J Pharm Pharm Sci 2011, 14:264-273.